Systems Biology Strategy Reveals PKCδ is Key for Sensitizing TRAIL-Resistant Human Fibrosarcoma

Area of Science:

• Oncology
• Computational Biology
• Molecular Biology

Background:

• Cancer cells exhibit high variability and resistance to therapies.
• Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) shows promise for targeted cancer treatment but faces resistance in some cancer types.
• Protein kinase C (PKC) was computationally identified as a key target to overcome TRAIL resistance.

Purpose of the Study:

• To experimentally validate the computational model's prediction of PKC as a target to enhance TRAIL efficacy.
• To investigate the mechanisms of cell death induced by combined TRAIL and PKC inhibition.
• To identify specific PKC isoforms crucial for cancer cell survival in TRAIL-resistant cells.

Main Methods:

• Experimental validation using TRAIL-resistant cancer cell lines (HT1080, HT29) and a PKC inhibitor (bisindolylmaleimide I).
• Assessment of cell viability, apoptosis markers (caspase-3, PARP activation), and signaling pathways (p38, JNK).
• Analysis of PKC isoform mRNA expression and targeted siRNA knock-down (KD) experiments.

Main Results:

• PKC inhibition with bisindolylmaleimide I resulted in over 95% cancer cell death for both HT1080 and HT29 cell lines, consistent with model predictions.
• Apoptosis was confirmed as the mechanism of cell death, evidenced by significant increases in caspase-3 and PARP activation.
• PKCδ was identified as the most effective isoform for inducing cancer cell death when knocked down in combination with TRAIL stimulation.

Conclusions:

• The combination of computational modeling and experimental validation provides a robust framework for identifying novel cancer therapeutic strategies.
• Targeting PKC, particularly PKCδ, in conjunction with TRAIL, represents a promising approach to overcome TRAIL resistance in various cancer types.
• This systems biology-driven approach holds potential for developing more effective cancer therapies.